RWMG
PMCB icon

Redwood Wealth Management Group’s PharmaCyte Biotech PMCB Stock Holding History

Redwood Wealth Management Group’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-69
Closed -$135 – 839
2024
Q2 		$135 Buy
+69
New +$149 ﹤0.01% 1166

Other funds holding PMCB

KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Redwood Wealth Management Group's PMCB Position: Q3 2024 in Review

Redwood Wealth Management Group sold out of PharmaCyte Biotech (PMCB) in Q3 2024, closing a stake of 69 shares — an estimated $135 sold.

Redwood Wealth Management Group first reported a position in PMCB in Q2 2024 and held it in 1 quarter. The position peaked at $135 in Q2 2024. 26 funds tracked by Wall St. Rank hold PMCB as of Q3 2024.

  • Redwood Wealth Management Group reported no remaining PharmaCyte Biotech position as of Q3 2024 after selling out during the quarter.
  • Redwood Wealth Management Group sold 69 PharmaCyte Biotech shares in Q3 2024, an estimated $135.
  • Redwood Wealth Management Group first reported a position in PharmaCyte Biotech in Q2 2024 and held it in 1 quarter.
  • Redwood Wealth Management Group's PharmaCyte Biotech position peaked at $135 in Q2 2024.
  • 26 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2024.

Based on Redwood Wealth Management Group's 13F filing for Q3 2024, filed 13 Nov 2024.